1. Home
  2. NUVL vs ALSN Comparison

NUVL vs ALSN Comparison

Compare NUVL & ALSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuvalent Inc.

NUVL

Nuvalent Inc.

HOLD

Current Price

$100.82

Market Cap

8.0B

Sector

Health Care

ML Signal

HOLD

Logo Allison Transmission Holdings Inc.

ALSN

Allison Transmission Holdings Inc.

HOLD

Current Price

$117.79

Market Cap

9.1B

ML Signal

HOLD

Company Overview

Basic Information
Metric
NUVL
ALSN
Founded
2017
1915
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Auto Parts:O.E.M.
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
8.0B
9.1B
IPO Year
2021
2012

Fundamental Metrics

Financial Performance
Metric
NUVL
ALSN
Price
$100.82
$117.79
Analyst Decision
Strong Buy
Hold
Analyst Count
15
7
Target Price
$135.00
$103.71
AVG Volume (30 Days)
497.6K
820.5K
Earning Date
02-27-2026
02-23-2026
Dividend Yield
N/A
0.93%
EPS Growth
N/A
N/A
EPS
N/A
8.15
Revenue
N/A
$3,069,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$0.88
P/E Ratio
N/A
$14.21
Revenue Growth
N/A
N/A
52 Week Low
$55.54
$76.01
52 Week High
$113.02
$118.75

Technical Indicators

Market Signals
Indicator
NUVL
ALSN
Relative Strength Index (RSI) 49.64 67.64
Support Level $98.65 $115.05
Resistance Level $106.57 $118.75
Average True Range (ATR) 4.46 2.35
MACD -0.29 -0.10
Stochastic Oscillator 47.36 68.29

Price Performance

Historical Comparison
NUVL
ALSN

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

About ALSN Allison Transmission Holdings Inc.

Allison Transmission is the largest manufacturer of fully automatic transmissions for medium- and heavy-duty commercial vehicles. Its automatic transmissions allow customers to achieve better fuel and operator efficiency than less expensive manual and automated manual transmissions. Allison serves several end markets, including on- and off-highway equipment and military vehicles. Its on-highway business commands approximately 60% global market share. The company's transmissions can be found in Class 4-8 trucks, buses, and a limited number of large passenger vehicles (heavy-duty pickup trucks and motorhomes). Allison also produces commercial hybrid propulsion systems and is developing fully electric powertrains.

Share on Social Networks: